Valuation: Beta Bionics, Inc.

Market Cap 577M 502M 467M 429M 810M 55.1B 822M 5.51B 2.16B 27.43B 2.17B 2.12B 91.98B P/E 2026 *
-5.99x
P/E 2027 * -5.96x
Enterprise Value 440M 382M 356M 327M 617M 41.99B 627M 4.2B 1.65B 20.91B 1.65B 1.62B 70.1B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 2.76x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day-10.09%
1 week-19.05%
1 month-23.45%
3 months+24.68%
6 months-6.35%
Current year-57.89%
1 week 12.79
Extreme 12.79
16.44
1 month 12.79
Extreme 12.79
18.2
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
6/24/26 A Sell

Executive/Senior Manager

-1,258 0.0028%
2/27/26 A Sell

Executive/Senior Manager

59,813 0.1359%
2/27/26 A Free

Chief Executive Officer

287,944 0.6541%
Change 5-day change 1-year change 3-year change Capi.($)
-10.09%-19.05%-21.77% - 577M
-0.43%+1.06%+24.03%+3.71% 212B
-0.61%+1.82%-1.07%-24.39% 137B
+0.10%+4.69%-26.86%+12.57% 125B
+1.59%+5.60%-55.67%-7.68% 69.46B
-0.98%+4.16%+8.50%+7.08% 49.56B
+5.94%+7.82%-17.08%-20.95% 47.2B
-0.25%-0.14%+21.91%+8.35% 39.08B
-0.79%+0.70%+29.97%+29.32% 37.05B
+0.00%+5.67%+116.67%+8.20% 30.97B
Average -0.46%+0.96%+7.86%+1.80% 74.81B
Weighted average by Cap. +0.40%+2.78%+3.90%-0.66%

Financials

2026 *2027 *
Net sales 134M 116M 108M 99.41M 188M 12.77B 191M 1.28B 501M 6.36B 503M 492M 21.32B 180M 156M 145M 134M 252M 17.16B 256M 1.71B 673M 8.54B 675M 660M 28.65B
Net income -95.09M -82.66M -76.94M -70.64M -133M -9.08B -135M -907M -356M -4.52B -357M -349M -15.15B -96.42M -83.81M -78.01M -71.62M -135M -9.2B -137M -920M -361M -4.58B -362M -354M -15.36B
Net Debt -137M -119M -111M -102M -193M -13.11B -196M -1.31B -514M -6.53B -516M -504M -21.88B -81.06M -70.47M -65.59M -60.22M -114M -7.74B -115M -773M -303M -3.85B -304M -298M -12.92B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
31/07/26 $12.83 -10.09% 2,004,597
30/07/26 $14.27 -5.93% 3,195,741
29/07/26 $15.17 -3.99% 1,673,555
28/07/26 $15.80 -1.19% 660,158
27/07/26 $15.99 +0.88% 850,682
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.83USD
Average target price
20.08USD
Spread / Average Target
+56.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock